drugset / Trial / NCT04762719

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

NCT04762719

Phase 2/3 Completed 12 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans. The researchers are trying to determine the utility of 11C-ER176 based PET-CT scanning to determine pro-inflammatory macrophage activation in gastric wall of patients with diabetic gastroparesis.

Timeline

Start
2021-05-10
Primary completion
2022-03-31
Completion
2022-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-ER176 Diagnostic / imaging agent 518 mbq Intravenous